Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Design Therapeutics, Inc. (DSGN)
Company Research
Source: GlobeNewswire
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTACTM Pipeline Programs in Huntington’s Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept CARLSBAD, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced first quarter 2024 financial results along with recent business highlights and upcoming milestones. “At Design, we began 2024 with a clear vision to advance our portfolio of first- or best-in-class therapies to treat major genetic disorders, using novel small molecules that work with a
Show less
Read more
Impact Snapshot
Event Time:
DSGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSGN alerts
High impacting Design Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DSGN
News
- Prefilled Syringes Market to Hit $22.8 Billion by 2029, Driven by Innovation and Demand Surge [Yahoo! Finance]Yahoo! Finance
- Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones [Yahoo! Finance]Yahoo! Finance
- Design Therapeutics, Inc. (NASDAQ: DSGN) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $12.00 price target on the stock, up previously from $6.00.MarketBeat
- Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceGlobeNewswire
DSGN
Earnings
- 3/19/24 - Beat
DSGN
Sec Filings
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- DSGN's page on the SEC website